Summary
Company plans to refile its application for its gene therapy for a fatal brain disease after FDA dropped demands to give a placebo to some study subjects
Key Takeaways— 2 points
1Exclusive | FDA Gives Third Rare-Disease Drug Another Shot, Regenxbio Says - WSJ.
2Company plans to refile its application for its gene therapy for a fatal brain disease after FDA dropped demands to give a placebo to some study subjects.
Image source: The Wall Street Journal
Source
The Wall Street Journal
Category
business
Published
22 June 2026 at 11:23
Why This Matters
This story was curated by DOCFLiX.site from The Wall Street Journal as part of our daily briefing service. We select and present the most significant developments across Business, Technology, and Crime Scene to keep our readers informed with source-verified, primary-cited news coverage. The summary above is derived from the original reporting by The Wall Street Journal.